Gilead Sciences, Inc. (GILD) EPS Estimated At $1.67

January 22, 2018 - By Hazel Jackson

 Gilead Sciences, Inc. (GILD) EPS Estimated At $1.67
Investors sentiment increased to 1.03 in 2017 Q3. Its up 0.10, from 0.93 in 2017Q2. It is positive, as 96 investors sold Gilead Sciences, Inc. shares while 488 reduced holdings. 127 funds opened positions while 474 raised stakes. 957.62 million shares or 2.06% more from 938.32 million shares in 2017Q2 were reported.
Cypress Cap Grp Inc owns 42,245 shares. Carret Asset Mgmt Limited Liability Corporation holds 0.09% in Gilead Sciences, Inc. (NASDAQ:GILD) or 6,781 shares. Lowe Brockenbrough owns 19,195 shares. Putnam Limited Liability Co reported 0.84% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Arcadia Investment Mngmt Mi invested 0.03% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). 26,391 were accumulated by Raymond James Trust Na. Usca Ria Ltd Liability holds 0.68% or 74,226 shares. Cincinnati Fincl Corporation reported 3.45% stake. Moors Cabot Inc invested in 27,479 shares or 0.32% of the stock. Ing Groep Nv holds 0.74% or 474,691 shares. Rothschild Invest Corp Il has 19,354 shares for 0.18% of their portfolio. Parametric Portfolio Associates Limited Liability Com holds 0.32% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 3.54M shares. State Of Tennessee Treasury Department holds 0.41% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 984,609 shares. Pennsylvania-based Pnc Fincl Service Gp Inc has invested 0.05% in Gilead Sciences, Inc. (NASDAQ:GILD). Hsbc Hldg Public Limited Liability Company owns 2.75M shares or 0.36% of their US portfolio.

Since August 1, 2017, it had 0 insider purchases, and 12 sales for $43.50 million activity. Alton Gregg H sold 30,000 shares worth $2.37 million. Washington Robin L had sold 51,820 shares worth $4.40 million on Thursday, September 7. Meyers James R had sold 60,000 shares worth $4.99 million on Thursday, August 31.

Analysts expect Gilead Sciences, Inc. (NASDAQ:GILD) to report $1.67 EPS on February, 6.They anticipate $0.97 EPS change or 36.74 % from last quarter’s $2.64 EPS. GILD’s profit would be $2.18B giving it 12.12 P/E if the $1.67 EPS is correct. After having $2.23 EPS previously, Gilead Sciences, Inc.’s analysts see -25.11 % EPS growth. The stock decreased 0.23% or $0.19 during the last trading session, reaching $80.98. About 7.92 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since January 22, 2017 and is downtrending. It has underperformed by 38.50% the S&P500.

Gilead Sciences, Inc. (NASDAQ:GILD) Ratings Coverage

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 19 have Buy rating, 0 Sell and 11 Hold. Therefore 63% are positive. Gilead Sciences had 112 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Outperform” rating by Credit Suisse on Wednesday, January 20. The firm has “Outperform” rating given on Wednesday, September 14 by Credit Suisse. The firm has “Buy” rating given on Wednesday, October 28 by Maxim Group. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Buy” rating given on Wednesday, October 4 by RBC Capital Markets. On Friday, July 21 the stock rating was maintained by BMO Capital Markets with “Hold”. RBC Capital Markets maintained the shares of GILD in report on Wednesday, February 3 with “Outperform” rating. As per Wednesday, November 8, the company rating was maintained by Mizuho. Cowen & Co maintained the shares of GILD in report on Tuesday, July 25 with “Buy” rating. The rating was maintained by J.P. Morgan with “Buy” on Monday, July 24. Citigroup initiated the stock with “Buy” rating in Thursday, February 25 report.

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company has market cap of $105.78 billion. The company??s products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It has a 9.22 P/E ratio. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B.

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Fool.com which released: “2017 Was a Year to Forget for Gilead Sciences, Inc., but This Year Could Be Better” on January 12, 2018, also Seekingalpha.com with their article: “Gilead: Buy Or Wait?” published on January 08, 2018, Seekingalpha.com published: “2018 Is Gilead’s Year” on January 16, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Omaha.com and their article: “On Investments: CVS, Gilead Sciences hit the Casualty List” published on January 16, 2018 as well as Fool.com‘s news article titled: “The case for Gilead Sciences” with publication date: January 21, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: